LFWD News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

LF

Mkt Cap

$17.0M

Volume

23.90K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and PainAn independent peer-reviewed study published in the Internet Journal of Allied Health Sciences and Practice demonstrates that individuals with chronic spinal cord injury using Lifeward's ReWalk personal exoskeleton showed significant improvements in daily activity performance, satisfaction, and reduced pain compared to wheelchair use. All 12 study participants successfully performed kitchen tasks while standing, 10 performed grooming tasks, and 8 reported improvements in bowel and bladder function. The findings support ReWalk's clinical value as Lifeward expands commercial distribution and reports 13% year-over-year sales growth to $2.5 million in Q2 2026.GlobeNewswire Inc. · Sep 15, 2026

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed PlatformLifeward Ltd. announced the appointment of Dr. Keith D. Rose as Chief Medical Officer, promoting him from his previous role as Vice President of Medical Affairs. With 30 years of rehabilitation medicine experience, Dr. Rose will lead the company's global medical strategy as Lifeward expands its neurorehabilitation portfolio and advances its biomedical pipeline, including its Protein Oral Delivery platform and oral insulin candidate ORMD-0801.GlobeNewswire Inc. · May 19, 2026

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyLifeward Ltd. announced shareholder approval for a strategic partnership with Oramed Pharmaceuticals, integrating Oramed's POD™ oral delivery technology platform. The deal provides Lifeward with up to $47 million in capital while allowing the company to diversify from its core medical technology business into biotechnology. Oramed will manage and fund the POD™ platform's clinical development, while Lifeward maintains focus on profitability from its existing ReWalk® and AlterG® product lines.GlobeNewswire Inc. · Mar 13, 2026

Lifeward Regains Compliance with Nasdaq Minimum Bid Price RequirementLifeward Ltd. (Nasdaq: LFWD) announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 or more for at least 10 consecutive business days, achieved on March 9, 2026. The company's common stock will continue trading on The Nasdaq Capital Market. Lifeward is a medical technology company specializing in physical rehabilitation solutions including exoskeletons and anti-gravity systems.GlobeNewswire Inc. · Mar 11, 2026

Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage InsurersLifeward announced that Aetna has approved Medicare Advantage coverage for its ReWalk Personal Exoskeleton, joining Humana and UnitedHealthcare. The three insurers collectively represent approximately 16 million beneficiaries, significantly expanding access to the FDA-approved exoskeleton technology for individuals with spinal cord injuries.GlobeNewswire Inc. · Feb 17, 2026

Lifeward Names Almog Adar as New CFO, Strengthening Executive LeadershipLifeward Ltd. announced the appointment of Almog Adar as its new Chief Financial Officer, promoting him from his previous role as Vice President of Finance and Chief Accounting Officer.GlobeNewswire Inc. · Aug 13, 2025

Lifeward to Present at Sidoti Virtual Investor Conference on May 21Lifeward, a medical technology company, reported its Q1 2025 financial results and announced the completion of a research program with an Israeli consortium to integrate AI and exoskeletons.GlobeNewswire Inc. · May 19, 2025

Lifeward and CorLife Finalize Partnership to Expand Workers’ Compensation Access to ReWalk ExoskeletonLifeward and CorLife have finalized an agreement for CorLife to become the exclusive distributor of Lifeward's ReWalk Personal Exoskeleton for individuals with Workers' Compensation claims. This partnership aims to increase awareness and facilitate efficient processing of claims for the ReWalk Exoskeleton, which enables paralyzed individuals to stand and walk.GlobeNewswire Inc. · Mar 6, 2025

Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025Lifeward, a global leader in innovative medical technology, announced that it will release its fourth quarter and fiscal year-end 2024 financial results on March 7, 2025. The company will host a conference call and webcast to discuss the results.GlobeNewswire Inc. · Feb 28, 2025

Rehabilitation Robots Market Size Expected to Reach USD 1776.24 Mn by 2034The global rehabilitation robots market is expected to grow from $495.53 million in 2025 to $1776.24 million by 2034, driven by technological advancements, automation, and the growing elderly population.GlobeNewswire Inc. · Feb 21, 2025

LF

LFWDLifeward Ltd. Ordinary Shares

LFWD

Pay with—

Available Balance0.00

Your PositionYou don't own any LFWD yet.

Related Tickers

Earnings